Acadia Pharma (ACAD) Halted Ahead of FDA PDAC Review of NUPLAZID
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Needham & Company Remains Bullish on Acadia Pharma (ACAD) Following Positive FDA Vote on Nuplazid
March 30, 2016 6:49 AM EDTNeedham & Company reiterated a Buy rating and $49.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD) following a vote by the FDA Psychopharmacologic Drugs Advisory Committee in favor of Nuplazid approval for treatment of Parkinson's Disease Psychosis. Committee members generally viewed Nuplazid as effective, with a few... More
Acadia Pharma (ACAD) Resumes Trading at 5:45 PM ET
March 29, 2016 5:43 PM EDTAcadia Pharma (NASDAQ: ACAD) Resumes Trading at 5:45 PM ET
... MoreAcadia Pharma (ACAD) Announces Favorable FDA Panel Vote on NUPLAZID for the Treatment of Psychosis Associated with Parkinson's Disease
March 29, 2016 5:14 PM EDTACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) voted 12 to 2 that the benefits of NUPLAZID (pimavanserin) for the treatment of psychosis associated with Parkinsons disease outweigh the risks of... More
Acadia Pharma (ACAD) wins FDA panel backing for Nuplazid - Bloomberg
March 29, 2016 3:37 PM EDTAcadia Pharma (NASDAQ: ACAD) wins FDA panel backing for Nuplazid, according to Bloomberg.
... MoreAcadia Pharma's (ACAD) NUPLAZID Seen Effective in Parkinson's - FDA Panel
March 29, 2016 2:55 PM EDTAcadia Pharma (NASDAQ: ACAD) received a positive FDA panel vote for pimavanserin in treating at least one disease. The following question was posed Tuesday:
1. VOTE: Has Acadia provided substantial evidence of effectiveness for NUPLAZID (pimavanserin) for the treatment of psychosis w/ PD?
12 panelists voted 'yes,' while 2 voted 'no.'
... MoreAcadia Pharma (ACAD) Said Facing 'Tough' Nuplazid Efficacy Questions from FDA Panel
March 29, 2016 10:14 AM EDTAcadia Pharma (NASDAQ: ACAD) is said to be facing tough questions on the efficacy of Nuplazid. The following was posted by pharma-watcher Adam Feuerstein to Twitter on Tuesday:
... More
Acadia Pharma (ACAD) trading halted with news pending
March 29, 2016 7:00 AM EDTAcadia Pharma (NASDAQ: ACAD) trading halted with news pending.
... MoreAcadia Pharma's (ACAD) Buy Rating Reiterated at H.C. Wainwright Ahead of Nuplazid's Adcom Meeting
March 28, 2016 7:52 AM EDTH.C. Wainwright reiterated a Buy rating on Acadia Pharmaceuticals (NASDAQ: ACAD) with a price target of $50. Comments follow the release of FDA briefing documents for tomorrow's Nuplazid FDA adcom panel. Analyst Andrew S. Fein said he remains confident that clinical benefits outweigh risks.
"As anticipated, the discussion will center on clinical meaningfulness of the 3-point improvement on SAPS-PD and risk/reward in light of safety signals, including potential... More
Leerink Affirms ACADIA Pharma (ACAD) at 'Outperform'; Pimavanserin Briefing Docs More Crticial than Expected
March 28, 2016 7:25 AM EDTLeerink affirms ACADIA Pharma (Nasdaq: ACAD) with an Outperform rating and $40 price target after the FDA Psychopharmacologic Drugs Advisory Committee released the pimavanserin briefing documents last Friday.
Analyst... More
Acadia Pharma (ACAD) Shares Active Ahead of NUPLAZID FDA Panel
March 28, 2016 7:03 AM EDTAcadia Pharma (NASDAQ: ACAD) shares advanced pre-market after the FDA posted briefing documents ahead of its NUPLAZID panel on March 29. The documents are embedded below:
... More